Journal
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
Volume 51, Issue 4, Pages 570-573Publisher
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.yjmcc.2010.09.020
Keywords
Thioredoxin1; Disulfide bond; Ischemia/reperfusion; Pathological cardiac hypertrophy; Recombinant; Small molecule
Categories
Funding
- U.S. Public Health Service [HL59139, HL67724, HL69020, HL91469, HL102738, AG27211]
- Foundation of Leducq Transatlantic Network of Excellence
Ask authors/readers for more resources
Thioredoxin 1 (Trx1) is a small molecule with reactive cysteines that reduces proteins with disulfide bonds through a thiol disulfide exchange reaction. Accumulating lines of evidence suggest that Trx1 protects the heart from ischemia/reperfusion injury, pathological hypertrophy, and inflammation; induces preconditioning effects and angiogenesis; and upregulates mitochondrial genes. Exogenously given recombinant Trx1 (r-Trx1) may protect the heart through its actions in both extracellular and intracellular spaces. In this brief review, the potential of Trx1 therapy for heart disease is discussed. This article is part of a special issue entitled Key Signaling Molecules in Hypertrophy and Heart Failure. (C) 2010 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available